Stock EYE NOVA EYE MEDICAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Nova Eye Medical Limited

Equities

EYE

AU0000094252

Market Closed - Australian S.E.
Other stock markets
 02:10:43 2024-05-01 EDT 		5-day change 1st Jan Change
0.265 AUD -5.36% Intraday chart for Nova Eye Medical Limited 0.00% +10.42%
03-15 Nova Eye Medical Completes Retail Entitlement Offer MT
02-22 Nova Eye Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
NOVA EYE MEDICAL LIMITED Stock Nova Eye Medical Limited
+10.42% 41.6M -
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.33% 217B
B
DANAHER CORPORATION Stock Danaher Corporation
+6.72% 183B
B-
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+10.18% 131B
B-
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+24.91% 106B
A-
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
-0.95% 62.16B
A-
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+10.56% 51.02B
B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+4.81% 50.89B
B+
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-0.24% 40.16B
A
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+1.22% 34.79B -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. EYE Stock
  4. Ratings Nova Eye Medical Limited